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The great success of anti-cytotoxic lymphocyte antigen 4 (CTLA4) and anti-programed
cell death protein 1 (PD1) in cancer treatment has encouraged more effort in harnessing
the immune response through immunomodulatory molecules in various diseases. The
immunoglobulin (Ig) super family comprises the majority of immunomodulatory molecules.
Discovery of novel Ig super family members has brought novel insights into the function
of different immune cells in tolerance maintenance. In this review, we discuss the function
of newly identified B7 family molecules, B7-H4 and V-domain Ig Suppressor of T cell
Activation (VISTA), and the butyrophilin/butyrophilin-like family members. We discuss the
current stages of immunomodulatory molecules in clinical trials of organ transplantation.
The potential of engaging the novel Ig superfamily members in tolerance maintenance
is also discussed. We conclude with the challenges remaining to manipulate these
molecules in the immune response.
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Introduction
The immune system consists of various cell types to mount both innate and adaptive immunity
against pathogens. As an important component of adaptive immunity, T cell activation requires
three signals. Signal 1 is acquired through the interaction between T cell receptor (TCR) and
peptide-loaded major histocompatibility complex (MHC) molecules. Signal 2 is induced through
the interaction between co-stimulatory/co-inhibitory molecules on antigen-presenting cells (APC)
and their receptors on T cells, thus enhancing/inhibiting T cell activation. Signal 3 is mediated by
cytokines, such as IL2 to promote T cell proliferation. Co-stimulatory/co-inhibitory molecules are
themost well-studiedmolecules and fall into immunoglobulin (Ig) super familymembers, including
B7 family and tumor necrosis factor (TNF) family proteins. These molecules play essential roles in
maintaining the balance between sufficient immune response against pathogenic antigens (Ag) as
well as limited response against self-antigens or allogenic transplant graft. We identify this family of
molecules as “immune modulatory molecules.” The potential receptors and ligands for many novel
molecules remain unknown and may serve as both receptors and ligands in different cells. In this
review, we define the potential receptors/ligands of these novel molecules as “binding partners” for
simplicity.
Over the past decade, a large number of B7 and TNF family molecules have been discovered
and actively evaluated in clinic. The clinical success of anti-CTLA4 (1, 2) and anti-PD1 blocking
antibody (Ab) (3, 4) in various cancers encourages more active research and drug development
effort. This effort aims to enhance co-stimulatory or dampening co-inhibitory molecules effect to
achieve robust anti-tumor immune response. In parallel, studies are also carried out to dampen the
immune response by enhancing the effect of co-inhibitory molecules in treatment of autoimmune
or inflammatory diseases (5–7). In addition, organ transplantation is still a great challenge in
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the clinic as the allogenic transplant rejection is a common prob-
lem in patients. There is great need for inhibiting the host rejection
of donor organs (8). Undoubtedly, the discovery of new immune
modulatory molecules has offered new opportunities to manip-
ulate the host immune system for tolerance maintenance and
graft acceptance. In this article, we review recent discoveries of
novel Ig B7 family members VISTA and B7-H4. We also review
the butyrophilin (BTN) family members, namely “old molecules
with novel immunomodulatory functions.” Learning from the on-
going clinical trials on well-described molecules, we discuss the
potential application of these new molecules.
B7 Family
B7 family proteins are among the best-described immunomodu-
latory molecules so far. This family consists of both co-inhibitory
and co-stimulatory molecules. This family includes B7.1 (CD80),
B7.2 (CD86), CD28, CTLA4, PD1, PD1 ligand (PDL1), PDL2,
B7RP1 (ICOSL), B7-H3, B7-H4, and VISTA. The growing list
of B7 family members offers great opportunities to modulate
immune response therapeutically in treating different diseases.
This family of molecules was reviewed elsewhere thoroughly
(9, 10). In the following section, we will discuss the progress
in understanding two new molecules in the family, B7-H4 and
VISTA.
B7-H4
B7-H4 (B7x, B7S1, VTCN1), identified in 2003 (11), is a highly
evolutionarily conserved molecule that shares 87% amino acid
identity between human andmouse.Mature B7-H4 is a 50–80 kDa
transmembrane protein with one IgV domain and one IgC
domain. The mRNA expression of B7-H4 is found on both
lymphoid and non-lymphoid tissues. However, B7-H4 protein
expression is more restricted and not expressed on ex vivo
human immune cells (T, B, DC, and monocytes), but can be
induced after in vitro stimulation. Endocrine cells in pancreas
have also been shown to express a moderate level of B7-H4.
Signaling through B7-H4 pathway leads to the inhibition of TCR-
mediatedCD4+ andCD8+ T cell proliferation, cell-cycle progres-
sion, and IL-2 production (11–13). In experimental autoimmune
encephalomyelitis (EAE) model, blocking B7-H4 on host cells by
a monoclonal antibody accelerates T cell responses and enhances
disease severity (11). However, B7-H4-deficient mice only mount
mildly increased Th1 response and intact cytotoxic T-lymphocyte
reactions against viral infections (14). The study indicated that
B7-H4 is a negative regulator of T cell activation but only plays
a minor role in fine-tuning T cell immunity. However, elevated
soluble form of B7-H4 in the serum of rheumatoid arthritis
(RA) patients is associated with increased disease severity. In a
collagen-induced arthritis mouse model, both overexpression of
soluble B7-H4 and genetic deletion of B7-H4 enhanced disease
severity, due to enhanced B cell, T cell, and neutrophil response
(15). This severity suggests that soluble B7-H4 acts as a decoy
molecule to block the inhibitory function of B7-H4. Further con-
firmation of the correlation between soluble B7-H4 and disease
severity in RA patients may indicate a new target pathway in
autoimmune diseases. Although soluble B7-H4-immunoglobulin
(B7-H4-Ig) fusion protein binds to activated T cells, the binding
partner for B7-H4 has not been identified and does not bind
to known CD28 family members, such as CD28, CTLA4, ICOS,
and PD1.
On the other hand, overexpression of B7-H4 on the pancre-
atic islets can protect mice from T cell-mediated autoimmunity
and these islet allograft increased survival after transplantation
(16). The immunosuppressive function of B7-H4 has also been
investigated in experimental type I diabetes models using B7-
H4-Ig. Pre-diabetic non-obese diabetes mice treated with B7-H4-
Ig displayed lower incidence of diabetes by suppressing immune
infiltrates into the islets (17). Lee et al. found that B7-H4-Ig
treatment decreased Th17 cell whereas promoting CD4+IFNγ+
T cells development (18). These findings suggest a possible role of
B7-H4 in maintaining the balance between Th1 and Th17 cells.
However, more studies are warranted to verify this observation
and elucidate the molecular mechanism. The impact of B7-H4 on
T cells is summarized in Figure 1.
FIGURE 1 | B7-H4 is a co-inhibitory molecule on APC (blue) and
interacts with its unknown receptor (receptor X) on T cells (green)
to deliver negative signaling during T cell activation. Left: in the
presence of B7-H4-receptor X interaction, T cells proliferate at a lower rate
and produce lower amount of IL2 (purple), lower IFNγ (black), and higher
IL17 (red). Middle: antagonistic anti-B7-H4 (magenta triangle) blocks the
interaction between B7-H4 and receptor X. T cells proliferate at a higher
rate and produce more IL2. Right: B7-H4 overexpression leads to lower
T cell proliferation, lower IL2 and IL17 production, and higher IFNγ
production.
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In addition to the direct impact of B7-H4 inhibition on T and B
cell immune response, B7-H4 also acts as a negative regulator for
neutrophil response. B7-H4-deficient mice are more resistant to
infection by Listeria monocytogenes due to augmented neutrophil
accumulation (19).Within 3 days after infection, bacterial colonies
in liver and spleen are significantly lower in B7-H4-deficient mice
than controls, concomitant with increased number of neutrophils
in the spleen of infected mice. B7-H4 inhibits the growth of
bone marrow-derived neutrophil progenitors in vitro, demon-
strating an inhibitory function of B7-H4 in neutrophil expansion.
Enhanced neutrophil growth in B7-H4-deficient mice also occurs
in the background of recombination activation gene (RAG) knock
out mice, independent of adaptive immunity. The inhibition of
neutrophil expansion shows that B7-H4 directly regulates innate
immunity. Furthermore, Pawar et al. discovered B7-H4 expres-
sion on kidney resident cells and could be induced further with
inflammatory stimuli. In an antibody-mediated nephritis model,
B7-H4-deficient mice showed more T, B, macrophage, and neu-
trophil infiltration into kidney. In addition, macrophages in B7-
H4-deficient mice demonstrate a more inflammatory phenotype.
Whether B7-H4modulates other immune cells remains unknown.
V Domain-Containing Ig Suppressor of
T-Cell Activation
V domain-containing Ig suppressor of T-cell activation (VISTA),
also named as PD1 homolog (PD1H), is expressed in both
hematopoietic and non-hematopoietic tissues. Among immune
cells, VISTA is highly expressed on mature CD11bhigh myeloid-
derived APCs and to a less extent on CD4+, CD8+, and Tregs
(20). VISTA is a 55- to 65-kDa type I Ig membrane protein
with the extracellular domain homologous to PD-L1. In vitro,
VISTA-Ig inhibits T cell activation, proliferation, and production
of cytokines, such as IL2 and IFNγ, during anti-CD3 activation.
VISTA overexpression on APC also suppressed T cell prolifera-
tion, which was rescued by neutralizing anti-VISTA monoclonal
Ab (13F3). More importantly, VISTA overexpression on tumor
cells overcame the protective anti-tumor immunity. These studies
collectively suggest that VISTAonAPCdelivers negative signaling
to T cells during activation via a yet-to-identify binding partner on
T cells. The same Ab administration in vivo exacerbated disease
progression in a passive EAEmodel. Further studies demonstrated
that mice deficient in VISTA display normal hematopoietic devel-
opment. These mice do not succumb to obvious organ-specific
autoimmune diseases, despite chronic inflammation in multiple
organs over age. Consistently, spontaneously activated T cells
accumulate and produce inflammatory cytokines and chemokines
in aged VISTA-deficient mice (21). 2D2 T cell receptor mice
overexpress T cell receptor that recognizes myelin oligodendro-
cyte glycoprotein (MOG35–55). VISTA deletion in 2D2 transgenic
mice significantly enhanced EAE severity. Disease progression
is due to an increase in activated encephalitogenic T cells in
the periphery and greater infiltration into the central nervous
system. The analysis of both VISTA-Ig and genetic ablation
demonstrated that VISTA is a negative check-point regulator of
T cell activation. Blocking VISTA’s function promotes the pro-
inflammatory cytokines production and enhances autoimmune
diseases development under susceptible conditions. However,
another anti-VISTAAb seemed to inhibit the progression of acute
graft-versus-host-diseases (GVHD). This inhibition indicates the
agonistic effect of this Ab in the regard of suppressing T cell
activation (22).
Even though the binding partner of VISTA remains unknown,
Flies et al. demonstrated that VISTA is a co-inhibitory receptor
on CD4+ T cells. VISTA /  CD4+ T cells showed stronger
Ag-specific proliferation and cytokine production than wild-type
CD4+ T cells. In an APC-T co-culture study, VISTA deficiency
on both APC and T cells resulted in the strongest proliferation
response, whereas VISTA-sufficient APC and T cells generated
the poorest response. VISTA deficiency on either APC or T cells
yielded an intermediate response. Taken this data together with
previous studies (20), VISTA negatively regulates T cell immunity
via direct impact on T cells by engaging different receptor/ligand
(illustrated in Figure 2). In a murine model of acute hepatitis, a
different agonistic VISTA Ab administration suppressed CD4+ T
cell andNK cell-mediated acute inflammation. The data suggested
that VISTA /  mice showed survival benefits during GL261
glioma growth, mediated by enhanced CD4+ T cell anti-tumor
immunity (22). The bidirectional inhibition ofVISTAonAPCand
T cells suggests that VISTA is a valuable target for immunological
diseases. The studies in mice are reinforced by characterization
of human VISTA expression and function (23). More studies are
needed to characterize the correlation between VISTA expression
and autoimmune diseases, such as RA, to establish the rationale
for targeting VISTA in clinic. Moreover, it is worthwhile evaluat-
ing the potential of agonistic anti-VISTA Ab in tolerance induc-
tion during organ transplantation given the preclinical evidences
in GVHD. Furthermore, the identification of VISTA’s binding
partner will certainly offer great insight into the molecular mech-
anism of VISTA signaling and ensure better understanding of
agonistic Ab safety in development.
Butyrophilin Family in Immune Tolerance
As B7 family member proteins, BTN family members have extra-
cellular IgV and IgC domain, but most BTN family members have
an intracellular B30.2 domain. Therefore, BTN family members
belong to the Ig superfamily. Since the discovery of BTN family
FIGURE 2 | VISTA is a co-inhibitory molecule on both APC (blue) and
T cells (green). VISTA is expressed on APC and interacts with the partner
(receptor X) on T cells. VISTA can also be a co-inhibitory receptor on T cells
and binds to its unknown ligand (ligand Y) on APC. Both interactions deliver
negative signaling to T cell activation.
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members in the regulation of immune response, butyrophilin-
like (BTNL), family members have also been identified in both
human andmouse genome. The extracellular structural similarity
between BTN/BTNL and B7 family suggested that BTN/BTNL
family molecules may have immune regulatory functions as B7
family members. In this section, we discuss the genomic distribu-
tion, function, and clinical evidence between BTN/BTNL family
proteins and immune tolerance.
Genomic Distribution of BTNs
The first BTNmember was discovered inmilk in which BTN sub-
family 1memberA1 (BTN1A1) is essential for the secretion, lacta-
tion, and stabilization ofmilk-fat globules (24–26). Further studies
discovered more BTN proteins with immune-regulatory func-
tions. Thus far, 13 human BTNs and BTNLs have been described.
Human BTNs include BTN1A1, BTN2A1, BTN2A2, BTN2A3,
BTN3A1, BTN3A2, and BTN3A3 (27). Human BTNLs include
BTNL2, BTNL3, BTNL8, BTNL9, BTNL10, and SKINT-like
(SKINTL). In mice, 11 genes have been identified to encode BTN
and BTNL molecules. These include BTN1A1, BTN2A2, BTNL1,
BTNL2, BTNL4, BTNL5, BTNL6, BTNL7, BTNL9, BTNL10, and
SKINT. Themajority of these proteins are diverse between human
andmice,making it difficult to study their function. Asmentioned
above, the BTN family members have extracellular IgV and IgC
domains as B7 family proteins (28–31). Extracellular IgV and
IgC domains are essential for the interaction among B7 family
members. However, it remains unknown whether BTN/BTNL
family proteins bind to their counter-receptors via the IgV and IgC
domain. In addition, it remains unknown how intracellular B30.2
domain binds to other intracellular signaling proteins to deliver
the function of BTNs and BTNLs. Regarding the expression pat-
tern of BTN/BTNL family molecules, there is some inconsis-
tency among existing data when comparing mRNA with protein
expression. Abeler-Dorner et al. summarized the mRNA and
protein expression of each BTN/BTNL family member in another
review (27).
Function of Butyrophilin in T cell Immunity
The wide distributions of certain BTN/BTNLs determine the
functions of these molecules in different immune cells. As
BTN/BTNLs are expressed on APCs or T cells, studies have been
carried out to determine the function of these molecules in the T
cell immunity in vitro and in vivo. In this section, we will focus
on the function of these “old molecules” in regulation of T cell
immunity, in the regard of both conventional αβ T cells and γδ
T cells.
Butyrophilin in Regulation of Conventional
T Cell Response
As B7 family members, some BTN/BTNLs are co-inhibitory
whereas others are co-stimulatory in the regard of conven-
tional T cell function regulation. The function characterization
of BTN/BTNL family members depends on the administration
of recombinant protein and antagonistic/agonistic Ab in T cell
activation, differentiation, and cytokine production in vitro and
diseases progression in vivo. In the following section, we will focus
on the delineation of co-inhibitory and co-stimulatory function of
various BTN/BTNL family members.
BTNs as co-inhibitory molecules
Nguyen et al. first demonstrated the co-inhibitory role of mouse
BTNL2 in T cell immunity (32). Mouse BTNL2-Ig fusion pro-
tein inhibited anti-CD3- and anti-CD28-stimulated CD4+ T cell
proliferation and IL2 production via reducing activating protein-
1 (AP-1), nuclear factor of activating T cells (NFAT), and NF-
κB activity. Arnett et al. further illustrated the upregulation of
BTNL2 in inflamed colons in themouseMdr1a-deficientmodel of
inflammatory bowel diseases. BTNL2 conveys its inhibitory signal
also by counteracting the co-stimulatory effect of B7RP1 (ICOS
ligand) on T cell activation (33). No binding partner has been
successfully identified as BTNL2 failed to bind known B7 family
proteins, such as CD28, ICOS, PD1, CTLA4, and HVEM.
Further studies elucidated the similar co-inhibitory function
of murine BTNL1 (34). In vitro studies showed that BTNL1-Ig
fusion protein suppressed low-concentration anti-CD3-induced
T cell activation and IL2 production by cell-cycle arrest. Like
BTNL2, BTNL1 does not bind CD28, CTLA4, triggering recep-
tor expressed on myeloid cells (TREM)-like transcript 2 (TLT-2,
TREML2), B7-H3, B7-1, or other B7 family members. Antago-
nistic anti-BTNL1 Ab-induced strong Th2 response after keyhole
limpet hemocyanin (KLH) and complete Freund’s adjuvant (CFA)
immunization in vivo, demonstrated by enhanced T cell prolif-
eration and higher production of Th2 cytokines (IL-4, IL-5, and
IL-13), but lower IFNγ. Antagonistic anti-BTNL1 Ab treatment
also exacerbated EAE via promoting Th17 response. Similarly,
α-BTNL1 Ab exacerbated Th2-mediated allergy response. These
studies indicate that BTNL1 may fine tune Th1 versus Th2 and
Th17 development. No potential BTNL1 binding partner has been
identified so far.
Human BTN3A1, also known as CD277, is highly upregu-
lated in myeloid DCs and macrophages by vascular endothe-
lial growth factor (VEGF) and CCL3 in human ovarian cancer.
BTN3A1 inhibited T cell proliferation and Th1 cytokine pro-
duction through preventing the upregulation of cellular caspase-
8 (FLICE)-like inhibitory protein (cFLIP) and the consequently
enhanced caspase-8 activity. Caspase-8 activity is necessary to
initiate the activation of NF-κB and promote T cell proliferation
(35). A recent study, however, extended the function of BTN3A1
beyond the co-inhibition to presenting phosphorylated antigen
(discussed in more details below).
Even though the preclinical studies highlighted the importance
of these co-inhibitory BTN/BTNLs in inflammatory diseases and
possibly graft tolerance, key issues remain for therapeutic target-
ing of these molecules. First, little is known regarding how the
negative signaling to T cell activation is conveyed by the engage-
ment with their potential binding partners. The understanding
in this regard will facilitate the identification of pharmacologi-
cal kinetics (PK) and pharmacological dynamics (PD) markers
during therapeutic Ab screening. Second, no potential binding
partners for these molecules have been identified. To enhance
the negative effect of the molecules during APC–T cell interac-
tion, it is essential to minimize unwanted effects by activating
potentially complex signaling pathway in T cells. More studies are
needed to gain better understanding of the function of these co-
inhibitory molecules in various T cell subsets differentiation and
other immune cells. This will help to determine the specific need
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of the Ab isotype or the format of BTN/BTNL-Ig fusion protein to
deliver the most effective drug with least toxicity.
BTNs as co-stimulatory molecules
Among BTN/BTNL family members, BTNL8 and BTN3A2 are
co-stimulatory molecules. There is no ortholog of human BTNL8
in mice. BTNL8 mRNA is highly expressed on neutrophils rather
than T cells or myeloid cells. BTNL8 seems to bind resting
instead of activated T cells. The administration of BTNL8-Ig
enhanced anti-CD3-stimulated human CD4+ T cell proliferation
and cytokines production, such as IFNγ, TNFα, IL8, and IL10.
This study indicated that BTNL8-Ig functions at very early stage
of T cell activation (36). Surprisingly, BTNL8-Ig fusion protein
enhanced Ovalbumin and alum-stimulated primary Ab response
in mice. However, no studies have illustrated the reason for
cross-species activity of BTNL8-Ig. Therefore, the binding partner
of human BTNL8 may share high homology with its ortholog
in mice. BTNL3 shares high sequence similarity BTNL8 but is
expressed mainly in neutrophils. No known function of BTNL3
has been reported. In a population genetics study, Aginel et al.
identified a BTNL8–BTNL3 deletion leading to a new BTNL8*3
fusion protein (37). The sequence between intron 4 of BTNL8
and intron 4 of BTNL3 is deleted, leading to no coding sequence
changes in BTNL8–BTNL3. Thus, the fusion protein may still
be intact. Gene-expression analysis in lymphoblastoid cell lines
showed that BTNL8–BTNL3 deletion is correlated with TNF and
ERK1/AKT pathways, the key players in immune regulation.
However, function analysis needs to be done. Further studies are
warranted to elucidate the correlation between BTNL8–BTNL3
deletion and inflammatory diseases in patients.
BTN3A2 was recognized as a co-stimulatory molecule from
correlation studies in cancer patients. Earlier studies suggested
that high BTN3A2 mRNA expression was associated with a good
prognosis in relation to disease-free and overall survival in a
cohort of 55 epithelial ovarian cancer (EOC) patients (38). Further
studies in a larger cohort of 199 high-grade EOC patients con-
firmed that the protein expression of BTN3A2 in ovarian cancer
tissues is positively correlated with the intraepithelial infiltration
of CD4+ and CD8+ T cells (39). The validation of BTN3A2 as a
prognosticmarker for EOC indicated that BTN3A2maymodulate
the infiltration of immune cells and thus the anti-cancer immu-
nity. To better understand whether BTN3A2 can be a therapeutic
target in cancer, inflammatory diseases, or transplant tolerance,
the function of BTN3A2 in specific immune cells warrants further
studies.
BTN as Antigen Presentation Molecule
A very recent study demonstrated the function of BTN3A1
beyond the co-inhibitory and co-stimulatory roles in immune
modulation (40, 41). Human Vγ9Vδ2 T cells are activated
by phosphorylated antigens. Theses antigens include host
isopentenylpyrophosphate (IPP) and microbial (E)-4-hydroxy-
3-methyl-but-2-enyl pyrophosphate (HMBPP). Vavassori et al.
discovered that recombinant BTN3A1 specifically stimulated
human Vγ9Vδ2 T cells in the presence of IPP. This effect is
independent of CD1d molecule. BTN3A1 binds to IPP at a
stoichiometry ratio of 1:1 at a lower affinity (Kd= 10 6 M)
than the binding of MHC to peptides (Kd= 10 7 10 9 M).
However, phosphorylated antigens can be pulsed on APCs,
indicating that they are bound by BTN3A1 under assay and
physiological conditions. Direct binding between BTN3A1
and Vγ9Vδ2 T cells was specific and weak in the absence
of IPP. However, BTN3A1 and Vγ9Vδ2 T cells binding is
facilitated by IPP engagement. This new role of BTN3A1 is
far beyond co-stimulatory molecules in conventional αβ T
cells as reported previously (35). Human Vγ9Vδ2 T cells are
critical components of protective anti-microbial and anti-cancer
immunity that involve cells that upregulate IPP. Therefore, it is of
great value to understand how BTN3A1 modulates Vγ9Vδ2 cells
in inflammatory diseases and cancer patients. Therapeutic effect
of targeting BTN3A1 may depend on the function of Vγ9Vδ2
in specific diseases. Therapeutic targeting of BTN3A1 may
potentially expand the bandwidth of immune regulation in clinic.
Function of BTN/BTNL in APC
In addition to co-inhibitory function of BTNL1 T cell immunity, a
recent study focused on the function in enterocytes (42). BTNL1
is highly expressed in small intestine, particularly on all entero-
cytes in close juxtaposition with T cells. When an enterocyte-
derived cell line is transfected with Btnl1, CD8αβ+TCRαβ+ and
CD8αα+γδ intraepithelial lymphocytes-induced cytokine pro-
duction was inhibited in a cell–cell contact-independent manner.
The cytokines include IL6, CXCL1, CCL4, and IL15. However,
monocyte chemoattractant protein-1 (MCP1), IFNγ, and CCL2
remained unchanged by Btnl1 overexpression. As epithelial cells
are protective sites where infection occurs frequently, the capabil-
ity of BTNL1 to dampen the response of enterocytes to activated
intraepithelial lymphocytes may be essential for leveraging colitis
and colon cancer. The close juxtaposition between BTNL1 and
cell receptor suggested that the interaction between intraepithelial
lymphocytes and enterocytes plays an essential role in sustaining
the integrity of colon tissues. Nevertheless, it remains unknown
whether BTNL1 controls the development of colon inflammation
in vivo or not. More in vivo studies using the specific deletion or
overexpression of BTNL1 in enterocytes may facilitate the under-
standing and therapeutic targeting of BTNL1 in inflammatory
diseases and tolerance induction.
Clinical Indication of BTN/BTNL and Immune
Tolerance
The first clinical association between BTN/BTNL proteins and
immune function modulation was identified between BTNL2
mutation and sarcoidosis (43). SNP analysis of 947 indepen-
dent and familial sarcoidosis cases identified a G–A transition
constituting rs2076530, leading to a mutant protein lacking the
C-terminal IgC domain and transmembrane helix. The mutant
protein fails to localize on the cell membrane and loses co-
inhibitory function, leading to over-activated T cells and thus
overt inflammation. Several other studies reported the increased
susceptibility to autoimmune sarcoidosis and myositis in patients
bearing BTNL2 mutations (44). In addition, studies also showed
correlation between BTNL2 polymorphism and ulcerative colitis
(45–47), tuberculosis (48), RA, and systemic lupus erythematosus
(49). However, more validation studies are required to establish
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the direct correlation between BTNL2 polymorphism and disease
progression or severity. Going frombench to bedside,more efforts
should be taken to understand the role of different BTN/BTNL
family members in modulating the function of specific immune
cells in various inflammatory diseases and organ transplantation.
Like some B7 family members, different BTN family members
can also interact with unknown binding partners in different
cell types, eliciting inhibitory or stimulatory response. Thorough
search for the binding partners of these BTN/BTNL members
will certainly facilitate the therapeutic development of agonist
or antagonist Ab or BTN-BTNL/Ig fusion protein in the organ
transplant maintenance. However, as transplant rejection is rather
complicated with various immune compartments involved, more
preclinical studies are warranted with any potential therapeutic
candidate. We will discuss below the current progress of manip-
ulating the well-understood immune modulatory molecules in
clinical development and what lessons we can learn from the past.
Transplant Tolerance in Clinical Practice
Transplant tolerance is still challenging in clinical practice,
although immunosuppression drugs, such as corticosteroids, have
been widely used in transplantation practice. Orlando et al. sum-
marized that out of 461 liver transplantation patients, 163 were
successful in maintaining the graft during immunosuppression
drugs withdrawal (50). On the contrary, there is only one case
report of operational tolerance in lung transplant (51) and one in
heart transplant (52).
To meet the clinical needs for tolerance maintenance, differ-
ent treatments have been developed by depleting effector B and
T cells, and enhancing the suppressive capability of Tregs and
tolerant DCs. Clinical trials are undergoing through depletion
of T cells using a-CD52 (53) and B cell depletion by anti-CD20
(Rituximab) (NCT00568477). Recent studies also explored the
efficacy of Treg adoptive transfer (NCT02088931) and bone mar-
row transplantation (54). To target effector cells and “regulatory”
cells simultaneously, some immunomodulatory molecules seem
practical based on the current data available in cancer studies.
Below, we will discuss specifically the drug development of check-
point regulators in clinic trial and what this means for future
work.
Numerous studies are testing the clinical feasibility of tar-
geting co-stimulatory or co-inhibitory molecules to treat both
autoimmune diseases and prolong organ transplant survival.
The earliest and most well-understood pathway is CD28/
CTLA4–CD80/CD86 pathway. In this regard, CTLA4-Ig fusion
protein (abatacept) was the first immune check-point regulator
drug approved for the treatment of RA with good safety profile
(5, 6). Abatacept binds to both CD80 and CD86, thus inhibiting
both co-stimulatory CD28 and co-inhibitory CTLA4 signaling
pathway. Early clinical trials of abatacept showed no significant
benefit in symptoms of mild atopic asthma (55), multiple sclerosis
(56), or ulcerative colitis (57). However, a second generation of
CTLA-Ig fusion protein (belatacept) has a lower disassociation
rate from CD80 and CD86 (58). In a Phase III trial of renal
transplantation, patients treated with belatacept and calcinurin
inhibitor showed superior function of renal transplants andmulti-
ple other clinical parameters (7, 59). However, belatacept-treated
patients also experienced a higher incidence and severity of acute
rejection episodes 1 year after transplantation than those patients
treated with calcinurin inhibitor only.
Further studies focused on antagonistic CD28 Ab (sc28AT) to
block the interaction between CD28 and CD80/CD86 without
disturbing the CTLA4 pathway. Non-human primate studies sug-
gested that the combination therapy of sc28AT and calcineurin
inhibitor induced CTLA4-dependent decrease of T cell function
and Treg promotion in the heart allografts in macaques (60). In
addition to the CD28/CTLA4 pathway, the CD40/CD154 pathway
has resurged as promising target in the clinic. Non-humanprimate
studies showed that non-depleting CD40 blocking Ab showed
efficacy in delaying rejection of bone marrow, islet (61), and renal
transplantation. Thus, a Phase IIa clinical trial is underway to
measure the efficacy of anti-CD40 (ASKP1240) in renal trans-
plantation (NCT01780844). The clinical trials of targeting these
pathways are summarized in Table 1.
As we learned from past experiences, different molecules may
contribute to various aspects of allograft rejection, through rest-
ing, activated, or memory T cell function regulation. Therefore,
more effort should be taken to understand the intercrossing sig-
naling pathways mediated by different molecules on APCs or
T cells. This will facilitate the identification of the appropriate
pathway to target with least side effects. The novel B7 family
members and BTN/BTNL members may play different roles than
other “old” molecules at different development stages of various
cell types. For instance, the high expression of B and T lym-
phocyte attenuator (BTLA) in γδ T cells (62) may suggest that
this molecule is important for modulating the pro-inflammatory
activities of γδ T cells. More studies are warranted to determine
TABLE 1 | Summary of the key clinical trials of targeting immune modulatory molecules and specific immune cells to gain immune tolerance.
Test agent Target Clinical trial number Trial phase Disease area Reference
Campath-1H (alemtuzumab) Anti-CD52 NCT00365846 Phase II Renal transplantation (53)
Rituximab Anti-CD20 NCT00568477 Phase II Renal transplantation N/A
Treg transfer Treg NCT02088931 Phase I Renal transplantation N/A
Abatacept CTLA4-lg NCT00048568, NCT00420199 Phase III Rheumatoid arthritis (5)
Abatacept CTLA4-lg NCT00784459 Phase II Mild atopic asthma (55)
Abatacept CTLA4-lg NCT01116427 Phase I/II Multiple sclerosis (56)
Abatacept CTLA4-lg NCT00410410 Phase III Ulcerative colitis (57)
Belatacept CTLA4-lg NCT00114777 Phase II Renal transplantation (7, 59)
NCT00346151 Phase III
ASKP1240 Anti-CD40 NCT01780844 Phase II a Renal transplantation N/A
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whether co-inhibitory molecules on γδ T cells play a significant
role in inflammatory diseases and allograft rejection.
The manipulation of both co-stimulatory and co-inhibitory
molecules in the clinic may bring promising outcomes in control
of tolerance maintenance. The incoming data from on-going and
future clinical trials will shed light on how different co-inhibitory
molecules can be engaged to tune down the host response against
the donor transplant. More characterization is required to under-
stand the specific impact of these drugs in facilitating Treg genera-
tion and inhibiting effector function. The selection of therapeutic
Ab isotypes and Ig fusion proteins takes thorough exploration to
determine the best therapeutic efficacy with least toxicity. On the
other hand, better understanding of the co-stimulatory molecules
will facilitate their function analysis in tolerance maintenance
during organ transplantation. The antagonistic Ab against the
costimulatory molecules may block the effector T and/or B cell
function by directly interfering with the ligand–receptor binding
on T cells. Alternatively, these molecules can also function via
interrogating the suppressive capability of myeloid cells. More
studies are needed to address the different functions of these
specific molecules in effector and regulatory cells.
Concluding Remarks
The discovery of various new Ig superfamily member proteins
has facilitated the clinical treatment of cancer, and tolerance
maintenance in inflammatory diseases and organ transplant. The
increasing effort on preclinical studies and drug development
toward these molecules will eventually determine the best single
agent or combinatorial approach with most desirable efficacy
and least toxicity. In our view, in-depth understanding of these
molecules in the following aspects is critical for clinical benefits.
First, in preclinical studies, it is of great importance to identify
the unknown binding partners and the down-stream signaling
pathways mediated by engagement of both co-inhibitory and
co-stimulatory molecules. The identification of binding partners
for known molecules, such as VISTA and B7-H4, is essential
for understanding the mechanism of antagonistic or agonistic
Ab/Ig fusion protein in altering the function of various immune
cells. Shared receptor(s)/ligand(s) among different Ig superfamily
molecules is not unusual, so the identification of binding part-
ners for new molecules will also help to determine the affected
pathways. The intracellular signaling pathway mediated by Ig
superfamily proteins engagement is critical for the assay devel-
opment during Ab or Ig fusion protein screening in drug devel-
opment. The recently established function of these molecules in
inflammatory cells, such as γδ T cells, offers a different angle
to target these molecules. Second, clinical studies need to focus
on the following aspects to better harness the immune system in
tolerance maintenance across different diseases. It is important to
establish the correlation between inflammation and BTN/BTNLs,
and other novel B7 family members in patients, such as RA,
transplant rejection, and so on. From on-going clinical trials,
extensive analysis of known immune check-point regulators may
shed new light on the optimal target molecules/immune cells. The
identification of biomarkers is critical for both the assessment
of efficacy and the understanding of mechanism of therapeutic
agents. Finally, in inflammatory diseases and organ transplanta-
tion treatment, combinatorial approaches targeting Ig superfamily
members with current standard of care regimes may potentially
offer enhanced therapeutic advantage. However, the complexity
of the disease severity and the transplant recipients need to be
evaluated carefully before determining the treatment regime due
to the potential danger of long-term immunosuppression. In con-
clusion, more studies will allow for better understanding both the
mechanism of these novel molecules in preclinical studies and
clinical trials for best development of therapeutic agents in various
diseases.
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